This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Myriad To Present Seven Clinical Studies At The Annual Clinical Genetics Meeting

SALT LAKE CITY, March 25, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that results from seven clinical studies will be presented at the upcoming American College of Medical Genetics (ACMG) annual meeting, which will be held Mar. 25-Mar.29, 2013 in Nashville, Tennessee.

"We believe clinical research is vital to advance the science surrounding hereditary cancer and genetic testing, and we are committed to sharing timely and accurate information about our research with the scientific and medical communities," said Richard Wenstrup, chief medical officer at Myriad. "Myriad will continue to be a pioneer in hereditary cancer testing, especially as we look to improve patient care with our next-generation, myRisk™ Hereditary Cancer panel."

Summaries of three of Myriad's key poster presentations at ACMG surrounding Myriad's testing process and the Company's myVision™ variant classification program are presented below:
Title: Align-GVGD, SIFT, Polyphen, MAPP-MMR, Grantham Analysis and Condel are weak
  predictors of the clinical significance of missense variants.
Presenter:  Iain Kerr
Date:  Friday, Mar. 28, 10:30 am to 12:00 pm CDT ( Poster 266)
Summary: This study analyzes several commonly utilized variant classification algorithms and 
  compares their performance to Myriad's proprietary variant classification program. The 
  study found that the accuracy of these algorithms was substantially lower than the 
  traditionally accepted threshold for clinical confidence.
Title:  Determining the clinical significance of silent BRCA1 and BRCA2 sequencing variants.
Presenter: Karla Bowles
Date:  Friday, Mar. 28, 10:30 am to 12:00 pm CDT ( Poster 302
Summary: Sequencing analysis of the BRCA1 and BRCA2 genes may identify mutations that are 
  predicted to be translationally silent. This study describes a testing algorithm used by 
  Myriad to determine the possible pathogenicity of silent mutations.
Title:  Assessment of laboratory-based quality control processes to ensure appropriate 
  utilization of genetic testing for hereditary cancer risk.
Presenter:  Serenedy Smith
Date: Thursday, Mar. 27, 10:30 am to 12:00 pm CDT (Poster 165)
Summary: This study evaluated BRAC Analysis ® and Colaris ® case submissions to evaluate whether 
  they met established clinical indications for testing based on patient histories. The study 
  found that only 0.5 percent of test orders lacked apparent clinical risk factors for the 
  ordered test and 93 percent met established clinical indications for testing consistent with 
  NCCN 2012 practice guidelines.

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website:

Myriad, the Myriad logo and Prolaris, Myriad myPath, Myriad myPlan, Myriad myRisk, are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN-G.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs